<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03748524</url>
  </required_header>
  <id_info>
    <org_study_id>201808171</org_study_id>
    <nct_id>NCT03748524</nct_id>
  </id_info>
  <brief_title>Analysis of Antigen Specific B Cell Responses to Immunization With Influenza Virus Vaccine</brief_title>
  <official_title>Washington University (WU) 321: Analysis of Antigen Specific B Cell Responses to Immunization With Influenza Virus Vaccine: Fine Needle Aspiration (FNA) and Bone Marrow Aspiration (BMA)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Washington University School of Medicine</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Washington University School of Medicine</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Immunization with the inactivated influenza vaccine with blood samples collected at 7 visits&#xD;
      (baseline, day 7, 14, 28, 60, 90 and 180, fine needle aspiration (FNAs) from axillary lymph&#xD;
      nodes at baseline, days, 4, 14, 28, 60 and 180. BMA at baseline, days 28 and 180.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">October 29, 2018</start_date>
  <completion_date type="Anticipated">October 29, 2021</completion_date>
  <primary_completion_date type="Anticipated">September 30, 2021</primary_completion_date>
  <phase>Early Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Determine the percentage of subjects achieving seroconversion</measure>
    <time_frame>0 and day 28</time_frame>
    <description>Change in serum hemagglutination-inhibition (HAI) antibody titers between day 0 to day 28</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Determine the frequency of vaccine-induced responses</measure>
    <time_frame>Day7</time_frame>
    <description>Frequency of vaccine-specific plasmablasts detected in blood at day 7 after vaccination</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">11</enrollment>
  <condition>Immunity, Cellular</condition>
  <arm_group>
    <arm_group_label>Single Influenza Vaccine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single Influenza Vaccine,Quadrivalent</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Influenza Vaccine</intervention_name>
    <description>Influenza Vaccine,Quadrivalent SIngle vaccination all participants at day 0</description>
    <arm_group_label>Single Influenza Vaccine</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Able to understand and give informed consent&#xD;
&#xD;
          2. Capable of attending all study visits according to the study schedule.&#xD;
&#xD;
          3. Males or females between the ages of 18 to 50 (inclusive).&#xD;
&#xD;
          4. Are in good health, as determined by medical history and targeted physical exam&#xD;
             related to this history.&#xD;
&#xD;
          5. Participants agree not to take any vaccines in the first 60 days after receipt of the&#xD;
             influenza vaccine&#xD;
&#xD;
          6. The following laboratory values obtained within 14 days prior to entry..&#xD;
&#xD;
               -  Absolute neutrophil count (ANC) ≥750 cells/mm3&#xD;
&#xD;
               -  Hemoglobin ≥11.0 g/dL for men and ≥10.0 g/dL for women&#xD;
&#xD;
               -  Platelet count ≥100,000/mm3&#xD;
&#xD;
               -  Creatinine clearance ≥60 mL/min estimated by the Cockcroft-Gault equation&#xD;
&#xD;
               -  Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) (SGPT) ≤5.0&#xD;
                  times upper limit of normal (ULN)&#xD;
&#xD;
          7. Willing to:&#xD;
&#xD;
               -  give FNA specimens for the study. (even if he/she are not willing to give bone&#xD;
                  marrow aspirates (for any reason), they can be enrolled)&#xD;
&#xD;
               -  give bone marrow aspirates, but we cannot locate axillary lymph nodes&#xD;
&#xD;
               -  give both FNA and BMA specimens&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  1. History influenza vaccination for the last three years.&#xD;
&#xD;
             2. Coagulopathy (primary or iatrogenic) which would contraindicate FNA&#xD;
&#xD;
             3. Any history of allergy to eggs, chicken or gelatin or to any previous influenza&#xD;
             vaccine&#xD;
&#xD;
             4. Have an acute illness within 72 hours before vaccination.&#xD;
&#xD;
             5. A history of a medical condition resulting in impaired immunity (such as HIV&#xD;
             infection, cancer, particularly leukemia, lymphoma, use of immunosuppressive or&#xD;
             antineoplastic drugs or X-ray treatment). Persons with previous skin cancers or cured&#xD;
             non-lymphatic tumors are not excluded from the study.&#xD;
&#xD;
             6. History of HIV infection, Hepatitis B or Hepatitis C infection&#xD;
&#xD;
             7. History of any chronic medical conditions that are considered progressive (ex,&#xD;
             diabetes, heart disease, lung disease, liver disease, kidney disease, gastrointestinal&#xD;
             diseases and uncontrolled hypertension).&#xD;
&#xD;
             8. History of excessive alcohol consumption, drug abuse, psychiatric conditions,&#xD;
             social conditions or occupational conditions that in the opinion of the investigator&#xD;
             would preclude compliance with the study.&#xD;
&#xD;
             9. Have taken oral or parenteral corticosteroids of any dose within 30 days before&#xD;
             study vaccination.&#xD;
&#xD;
             10. Have taken high-dose inhaled corticosteroids within 30 days before study&#xD;
             vaccination.&#xD;
&#xD;
             11. Autoimmune disorders; mild autoimmune disorders such as eczema is not exclusion&#xD;
             after assessment by the investigator.&#xD;
&#xD;
             12. Recipient of a blood products or immune globulin product within 42 days of the&#xD;
             vaccination visit.&#xD;
&#xD;
             13. Pregnant women and nursing mothers or women who are planning to become pregnant&#xD;
             for the study duration.&#xD;
&#xD;
             14. Have received any licensed live vaccine within 30 days or any licensed inactivated&#xD;
             vaccine within 14 days prior to study vaccination.&#xD;
&#xD;
             15. Have planned vaccination with any vaccine during first 60 days of study&#xD;
             participation.&#xD;
&#xD;
             16. Have received immunoglobulin or other blood products, with the exception of Rho D&#xD;
             immunoglobulin, within 90 days prior to study vaccination.&#xD;
&#xD;
             17. Have donated blood or blood products within 30 days before study vaccination, plan&#xD;
             to donate blood at any time during the duration of subject study participation, or&#xD;
             plan to donate blood within 30 days after the last blood draw.&#xD;
&#xD;
             18. Any condition in the opinion of the investigator that would interfere with the&#xD;
             proper conduct of the trial.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <gender_based>Yes</gender_based>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ali Ellebedy, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Washington University School of Medicine</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Washington University School of Medicine Infectious Disease Clinical Research Unit</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2021</verification_date>
  <study_first_submitted>November 15, 2018</study_first_submitted>
  <study_first_submitted_qc>November 16, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">November 21, 2018</study_first_posted>
  <last_update_submitted>January 5, 2021</last_update_submitted>
  <last_update_submitted_qc>January 5, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">January 6, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Influenza, B cells, Antibodies, Vaccination</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Influenza, Human</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

